Welcome to another exciting episode of our podcast featuring Justine Brophy from AnBro, a voice familiar to listeners. This week, we're revisiting Dexcom as a stock that AnBro holds in its Unicorn portfolio. It’s great to be able to track the journey of a specific stock through a volatile market, with Justine regularly coming onto the show to use it as a good example of how the team at AnBro reacts to market dynamics. This show discusses what the recent market turbulence and why does AnBro remain invested in the stock, despite a headache-inducing rollercoaster ride from $112 to $74 and back to $96 per share?
Use the podcast player below to listen to our discussion on Pfizer and its Q4'22 result, which accompanies the detailed write-up below: (Date of report: 9 February 2023) Pfizer had a momentous year in 2022. Not only did the company exceed $100bn in revenue for the first time in its 174-year history, but 1.3 billion patients around the world were treated with Pfizer products. Despite these glowing financial accomplishments, Pfizer is a constant target of conspiracy theories and political battles. There’s never a dull moment in the pharmaceuticals industry. Management at Pfizer is either overly optimistic about the prospects for the [...]
Use the podcast player below to listen to our discussion on Walgreens Boots Alliance and its Q3’22 result, which accompanies the detailed write-up below: (Date of report: 6 July 2022) Walgreens Boots Alliance is a pharmacy retail group that sounds like a defensive play at first blush. But as we will explore in this podcast and report, the business model of these types of retailers isn’t as robust as one may think, especially in the US where the pharmacy benefit managers hold incredible power in the value chain. It all comes down to gross margin, so product mix is critical. Dispensary [...]
The Finance Ghost and Mohammed Nalla (Moe-Knows) are back! In the opening episode of 2021, we touch on what worked and didn't work in our respective portfolios in 2020. We also talk about changes we've made for 2021 to position ourselves for latest market conditions, especially against a backdrop of second wave lockdowns. http://